- Wilkening DA. Modeling the incubation period of inhalational anthrax. Med Decis Making 2008;
28:593–605. - Wilkening DA. Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci U S A
2006; 103:7589–7594. - Frank SA, Jeffrey JS. The probability of severe disease in zoonotic and commensal infections. Proc
Biol Sci 2001; 268:53–60. - Stern EJ, Uhde KB, Shadomy SV, et al. Conference report on public health and clinical guidelines for
anthrax. Emerg Infect Dis 2008; pii:07–0969. - Athamna A, Athamna M, Medlej B, et al. In vitro post-antibiotic effect of fluoroquinolones,
macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol,
quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother 2004;
53:609–615. - Mayer TA, Bersoff-Matcha S, Murphy C, et al. Clinical presentation of inhalational anthrax following
bioterrorism exposure: report of 2 surviving patients. JAMA 2001; 286:2549–2553. - Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of botulism and
bioterrorism-related botulism. Euro Surveill 2004; 9:E13–E14. - Eliasson H, Broman T, Forsman M, et al. Tularemia: current epidemiology and disease management.
Infect Dis Clin North Am 2006; 20:289–312. - Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated
recommendations for management. JAMA 2002; 287:236–2252. - Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of brucellosis and
bioterrorism-related brucellosis. Euro Surveill 2004; 9:E15–E16. - Thibault FM, Hernandez E, Vidal DR, et al. Antibiotic susceptibility of 65 isolates ofBurkholderia
pseudomalleiandBurkholderia malleito 35 antimicrobial agents. J Antimicrob Chemother 2004;
54:1134–1138. - Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of glanders and
melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill 2004; 9:E17–E18. - Carcopino X, Raoult D, Bretelle F, et al. Managing Q fever during pregnancy: the benefits of long-
term cotrimoxazole therapy. Clin Infect Dis 2007; 45:548–555. - Krol V, Kogan V, Cunha BA. Q fever bioprosthetic aortic valve endocarditis (PVE) successfully
treated with doxycycline monotherapy. Heart Lung 2008; 37:157–160. - Karakousis PC, Trucksis M, Dumler JS. Chronic Q fever in the United States. J Clin Microbiol 2006;
44:2283–2287. - Morovic M. Q fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only?
Am J Trop Med Hyg 2005; 73:947–948. - Pratt TS, Pincus SH, Hale ML, et al. Oropharyngeal aspiration of ricin as a lung challenge model for
evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment.
Exp Lung Res 2007; 33:459–481. - Smallshaw JE, Richardson JA, Vitetta ES. RiVax, a recombinant ricin subunit vaccine, protects mice
against ricin delivered by gavage or aerosol. Vaccine 2007; 25:7459–7469. - Griffiths GD, Phillips GJ, Holley J. Inhalation toxicology of ricin preparations: animal models,
prophylactic and therapeutic approaches to protection. Inhal Toxicol 2007; 19:873–887. - Hoffman RJ, Hahn IH, Shen JM, et al. In vitro-activated charcoal binding of staphylococcal
enterotoxin B. Clin Toxicol (Phila) 2007; 45:773–775. - Buonpane RA, Churchill HR, Moza B, et al. Neutralization of staphylococcal enterotoxin B by
soluble, high-affinity receptor antagonists. Nat Med 2007; 13:725–729. - Azad AF. Pathogenic rickettsiae as bioterrorism agents. Clin Infect Dis 2007; 45(suppl 1):S52–S55.
- Stittelaar KJ, Tisdale M, van Amerongen G, et al. Evaluation of intravenous zanamivir against
experimental influenza A (H5N1) virus infection in the cynomolgus macaques. Antiviral Res 2008;
80:225–228. - Sugrue RJ, Tan BH, Yeo DS, et al. Antiviral drugs for the control of pandemic influenza virus. Ann
Acad Med Singapore 2008; 37:518–524. - Michaelis M, Kleinschmidt MC, Doerr HW, et al. Minocycline inhibits West Nile virus replication
and apoptosis in human neuronal cells. J Antimicrob Chemother 2007; 60:981–986. - Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS.
J Antimicrob Chemother 2008; 62:437–441. - Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in
non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45:1290–1295. - Budowle B, Beaudry JA, Barnaby NG, et al. Role of law enforcement response and microbial
forensics in investigation of bioterrorism. Croat Med J 2007; 48:437–449.
Bioterrorism Infections in Critical Care 485